These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 17136223)
21. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723 [TBL] [Abstract][Full Text] [Related]
23. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Chirnomas D; Smith AL; Braunstein J; Finkelstein Y; Pereira L; Bergmann AK; Grant FD; Paley C; Shannon M; Neufeld EJ Blood; 2009 Nov; 114(19):4009-13. PubMed ID: 19724055 [TBL] [Abstract][Full Text] [Related]
24. Deferasirox for transfusion-related iron overload: a clinical review. Lindsey WT; Olin BR Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472 [TBL] [Abstract][Full Text] [Related]
25. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Balocco M; Carrara P; Pinto V; Forni GL Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129 [No Abstract] [Full Text] [Related]
26. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. Galanello R; Piga A; Alberti D; Rouan MC; Bigler H; Séchaud R J Clin Pharmacol; 2003 Jun; 43(6):565-72. PubMed ID: 12817519 [TBL] [Abstract][Full Text] [Related]
27. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Taher AT; Temraz S; Cappellini MD Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402 [TBL] [Abstract][Full Text] [Related]
28. Deferasirox: pharmacokinetics and clinical experience. Galanello R; Campus S; Origa R Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640 [TBL] [Abstract][Full Text] [Related]
29. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949 [TBL] [Abstract][Full Text] [Related]
30. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129 [TBL] [Abstract][Full Text] [Related]
31. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome. Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738 [TBL] [Abstract][Full Text] [Related]
32. The oral chelator deferasirox--a new perspective for patients with iron overload. Fischer R Haematologica; 2006 Jul; 91(7):865A. PubMed ID: 16818263 [No Abstract] [Full Text] [Related]
33. Oral iron chelators. Cappellini MD; Pattoneri P Annu Rev Med; 2009; 60():25-38. PubMed ID: 19630568 [TBL] [Abstract][Full Text] [Related]
34. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987 [TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Karnon J; Tolley K; Oyee J; Jewitt K; Ossa D; Akehurst R Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348 [TBL] [Abstract][Full Text] [Related]
36. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes. Ricchi P; Marsella M Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673 [TBL] [Abstract][Full Text] [Related]
37. In brief: Jadenu--a new formulation of deferasirox for iron overload. Med Lett Drugs Ther; 2016 Apr; 58(1493):e56. PubMed ID: 27101213 [No Abstract] [Full Text] [Related]
39. Objectives and mechanism of iron chelation therapy. Hershko C; Link G; Konijn AM; Cabantchik ZI Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658 [TBL] [Abstract][Full Text] [Related]
40. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]